| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $217 to...
Biogen (NASDAQ:BIIB) lowers FY2025 Adj EPS guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 analyst estimate. sees sales ...
Biogen (NASDAQ:BIIB) lowers FY2025 Adj EPS guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 analyst estimate. Increased e...
Biogen (NASDAQ:BIIB) reported quarterly earnings of $4.81 per share which beat the analyst consensus estimate of $3.88 by 23.91...
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across mul...